Takeda Pharmaceutical Company Limited (TAK)
NYSE (ADR) / TSE · Tokyo, Japan · Founded 1781 · CEO Julie Kim
Valuation summary
$26.56 fair value versus $21.41 in the market, a difference of +24.1%. Rated Buy.
| Fair value per share | $26.56 |
| Current share price | $21.41 |
| Upside / downside | +24.1% |
| Bear case | $15.32 |
| Bull case | $42.66 |
| Discount rate (WACC) | 7.9% |
| Terminal growth | 1.50% |
| Market capitalisation | $69B |
| EV / Sales | 3.4x |
About Takeda Pharmaceutical Company Limited
Founded in 1781 when Chobei Takeda began selling traditional medicines in Osaka; it is Japan's largest drug maker. Julie Kim, who ran its US business, succeeded Christophe Weber as chief executive in 2026. Takeda became a global company by buying Shire for about $62 billion in 2019. It sells medicines for digestive diseases (Entyvio), rare diseases, cancer and neuroscience, and is one of the largest producers of therapies made from donated blood plasma.
Investment case
- A late-stage pipeline with several potential large products, including a narcolepsy medicine.
- Plasma therapies are a steady, growing business with few competitors.
- A high dividend yield.
Key risks
- Generic versions of the ADHD drug Vyvanse have cut sales, and Entyvio faces biosimilars later.
- Still carries substantial debt from the Shire deal.
- A weak yen and Japanese price cuts affect reported results.
Revenue by segment
| Gastroenterology | 30% |
| Plasma-derived therapies | 23% |
| Rare diseases | 17% |
| Oncology | 12% |
| Neuroscience | 12% |
| Vaccines and other | 6% |
Five-year forecast
| Revenue | Free cash flow | |
|---|---|---|
| Year 1 | $30.2B | $5.7B |
| Year 2 | $32.1B | $6.0B |
| Year 3 | $34.1B | $6.3B |
| Year 4 | $36.2B | $6.6B |
| Year 5 | $38.5B | $7.0B |
What the street says
Viewed as a low-growth income stock with pipeline upside that the market discounts.
Comparable companies: GSK · HCA · IQV · BIIB · TEVA · A · MDT · BSX
Open the interactive model, price chart and sensitivity grid →